Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
HOPE Against Cancer Recurrence in HCC
NCT06717919 · View on ClinicalTrials.gov ↗
Study Summary
Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received. Machine liver perfusion, for example, hypothermic oxygenated liver perfusion (HOPE), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers before implantation. The standard of care is cold storage without perfusion. The objective of this study is to compare the survival after tumor recurrence of patients after liver transplantation for HCC between perfused and not perfused livers. This study's hypothesis is that survival without tumor recurrence is improved when the liver is perfused before implantation. The study involves transplant centers worldwide, and adults with HCC waiting for liver transplantation are included. 220 Patients will be recruited within 12 months and then observed for at least 2 years after transplantation. To provide the most valid results, the patients will be randomly allocated to either the organ perfusion group or a control group with standard-of-care cold storage of the organ.
Conditions Studied
Interventions
- PROCEDURE Hypothermic oxygenated perfusion
- PROCEDURE Conventional cold storage
Study Locations (20)
Other
- Medical University of Innsbruck — Innsbruck
- Medical University of Vienna — Vienna
- University Hospitals Leuven — Leuven
- Institut de Recherche Expérimentale et Clinique (IREC) UCLouvain (Brussels) — Woluwe-Saint-Lambert
- Institute for Clinical and Experimental Medicine (IKEM) (Prague) — Prague
- Copenhagen University Hospital — Copenhagen
- Hôpital de la Croix-Rousse (Lyon) — Lyon
- Universitätsklinikum Essen — Essen
- University Medical Centre Hamburg-Eppendorf — Hamburg-Eppendorf
- Hannover Medical School — Hanover
- University of Heidelberg — Heidelberg
- University of Mainz — Mainz
- University of Munich Grosshadern — München
- Milano Institutio Nazionale dei Tumori (Milan) — Milan
- ASST Grande Ospedale Metropolitano Niguarda (Milan) — Milan
- Padova University Hospital — Padua
- Gemelli University Hospital — Rome
- University of Udine — Udine
New York
- Rutgers New Jersey Medical School (New York) — New York
Ohio
- Cleveland Clinic — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06717919
The ClinicalTrials.gov registry entry for NCT06717919 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philipp Dutkowski, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with HCC appearing as the primary indexed condition, and to 2 interventions — of which Hypothermic oxygenated perfusion is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06717919 reports 20 study locations spanning 3 distinct geographic areas — top geographies include Other, New York, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06717919 about?
NCT06717919 is a clinical study titled "HOPE Against Cancer Recurrence in HCC". Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this...
What is the current status of trial NCT06717919?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2025-08-01. Estimated completion is 2028-01-31.
What conditions does trial NCT06717919 study?
This clinical trial studies the following conditions: HCC, Liver Transplantation, Oncological Outcomes. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06717919?
The interventions under investigation include: Hypothermic oxygenated perfusion (PROCEDURE), Conventional cold storage (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06717919?
This trial is sponsored by Philipp Dutkowski, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06717919 being conducted?
This trial has 20 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.